RecruitingRecruiting
Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes
NCT07729150 · Dana-Farber Cancer Institute
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Reduce Hot flashEs AssociaTed With ADT (Reduce HEAT) - a Prospective Randomized Clinical Trial of a Wearable Thermal Device for Patients With Prostate Cancer on ADT With Bothersome Vasomotor Symptoms
About this study
This is a randomized, supportive care trial in which men with prostate cancer on ADT and experiencing bothersome hot flashes will be assigned to either immediate use of the Embr Wave device for 12 weeks or delayed use (usual care for 6 weeks, then device for 6 weeks). The Embr Wave is a commercially available wearable device that provides a cooling sensation and is being tested for its ability to reduce hot flash severity and improve quality of life. Participants will be enrolled across the DF/HCC consortium and collaborative sites.
Eligibility criteria
Inclusion Criteria:
* Patients with a clinical or pathologic confirmed diagnosis of prostate cancer
* Patients must be undergoing treatment with standard androgen deprivation therapy (i.e., GnRH agonist or antagonist) for ≥ 4 weeks. Patients must remain on ADT for the duration of the study (12 weeks); they may receive treatment with an androgen receptor pathway inhibitor (ARPI), radioligand therapy, or immunotherapy combined with ADT.
* Patients must report bothersome hot flash symptoms (defined as ≥ 28 hot flashes per week, perceived to be at least moderately bothersome to the patient), during a period of at least 30 days prior to entering the study.
* Age ≥18 years.
* ECOG performance status ≤ 2
* Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
* Pregnant and nursing women are excluded as prostate cancer is a disease of men.
* Participants with a concurrent diagnosis, including separate malignancy, that may limit life expectancy \< 6 months.
* Systemic antineoplastic therapy besides approved ARPI, radioligand therapy, and immunotherapy - enrollment in a clinical trial that is using SOC therapeutic options in these categories is allowed.
Study design
Enrollment target: 66 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-10-01
Estimated completion: 2028-06-01
Last updated: 2026-09-25
Interventions
Device: Embr Wave
Primary outcomes
- • Hot Flash Related Daily Interference Scale (HFRDIS) Score (Assessed 6 weeks after randomization)
Sponsor
Dana-Farber Cancer Institute · other
Contacts & investigators
ContactDaniel Sentana Lledo, MD · contact · daniel_sentanalledo@dfci.harvard.edu · 617-632-3466
InvestigatorDaniel Sentana Lledo, MD · principal_investigator, Dana-Farber Cancer Institute
All locations (1)
Dana-Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States